SLC5A1 and type 2 diabetes mellitus: The recent findings from the SCORED (10,584 patients with type 2 diabetes and CKD randomized to sotagliflozin or placebo) and SOLOIST (1222 patients with type 2 diabetes admitted with worsening heart failure randomized to sotagliflozin or placebo) trials suggest that like SGLT2is, SGLT1/2 s reduce the composite of deaths from cardiovascular causes, hospitalization for heart failure, and urgent visits for heart failure but may provide greater reduction in MI and stroke [5, 6].